Junhao Wen,Zhijian Yang,Ilya M. Nasrallah,Yuhan Cui,Guray Erus,Dhivya Srinivasan,Ahmed Abdulkadir,Elizabeth Mamourian,Ioanna Skampardoni,Gyujoon Hwang,Ashish Singh,Mark Bergman,Jingxuan Bao,Erdem Varol,Zhen Zhou,Aleix Boquet-Pujadas,Jiong Chen,Arthur W. Toga,Andrew J. Saykin,Timothy J. Hohman,Paul M. Thompson,Sylvia Villeneuve,Randy Gollub,Aristeidis Sotiras,Katharina Wittfeld,Hans J. Grabe,Duygu Tosun,Murat Bilgel,Yang An,Daniel S. Marcus,Pamela LaMontagne,Tammie L. Benzinger,Susan R. Heckbert,Thomas R. Austin,Lenore J. Launer,Mark Espeland,Colin L Masters,Paul Maruff,Jurgen Fripp,Sterling C. Johnson,John C. Morris,Marilyn S. Albert,R. Nick Bryan,Susan M. Resnick,Luigi Ferrucci,Yong Fan,Mohamad Habes,David Wolk,Li Shen,Haochang Shou,Christos Davatzikos

Abstract:Alzheimer’s disease (AD) is associated with heterogeneous atrophy patterns. We employed a semi-supervised clustering technique known as Surreal-GAN, through which we identified two dominant dimensions of brain atrophy in symptomatic mild cognitive impairment (MCI) and AD patients: the “diffuse-AD” (R1) dimension shows widespread brain atrophy, and the “MTL-AD” (R2) dimension displays focal medial temporal lobe (MTL) atrophy. Critically, only R2 was associated with widely known sporadic AD genetic risk factors (e.g., APOE ε4 ) in MCI and AD patients at baseline. We then independently detected the presence of the two dimensions in the early stages by deploying the trained model in the general population and two cognitively unimpaired cohorts of asymptomatic participants. In the general population, genome-wide association studies found 77 genes unrelated to APOE differentially associated with R1 and R2. Functional analyses revealed that these genes were overrepresented in differentially expressed gene sets in organs beyond the brain (R1 and R2), including the heart (R1) and the pituitary gland, muscle, and kidney (R2). These genes were enriched in biological pathways implicated in dendritic cells (R2), macrophage functions (R1), and cancer (R1 and R2). Several of them were “druggable genes” for cancer (R1), inflammation (R1), cardiovascular diseases (R1), and diseases of the nervous system (R2). The longitudinal progression showed that APOE ε4 , amyloid, and tau were associated with R2 at early asymptomatic stages, but this longitudinal association occurs only at late symptomatic stages in R1. Our findings deepen our understanding of the multifaceted pathogenesis of AD beyond the brain. In early asymptomatic stages, the two dimensions are associated with diverse pathological mechanisms, including cardiovascular diseases, inflammation, and hormonal dysfunction – driven by genes different from APOE – which may collectively contribute to the early pathogenesis of AD.### Competing Interest StatementDAW served as Site PI for studies by Biogen, Merck, and Eli Lilly Avid. He has received consulting fees from GE Healthcare and Neuronix. He is on the DSMB for a trial sponsored by Functional Neuromodulation. AJS receives support from multiple NIH grants, P30 AG010133, P30 AG072976, R01 AG019771, R01 AG057739, U01 AG024904, R01 LM013463, R01 AG068193, T32 AG071444, and U01 AG068057 and U01 AG072177. He has also received support from Avid Radiopharmaceuticals, a subsidiary of Eli Lilly, in kind contribution of PET tracer precursor, Bayer Oncology Scientific Advisory Board, Eisai Scientific Advisory Board, Siemens Medical Solutions USA, Inc. Dementia Advisory Board, Springer-Nature Publishing Editorial Office Support as Editor in Chief, Brain Imaging, and Behavior. ME receives support from multiple NIH grants, the Alzheimers Association, and the Alzheimer Therapeutic Research Institute. HJG has received travel grants and speaker honoraria from Fresenius Medical Care, Neuraxpharm, Servier, and Janssen Cilag as well as research funding from Fresenius Medical Care. HJG had personal contracts approved by the university administration for speaker honoraria and one IIT with Fresenius Medical Care. AA was supported by grants 191026 and 206795 from the Swiss National Science Foundation

Cerebrospinal fluid proteomics define the natural history of autosomal dominant Alzheimer's disease

Identification of Candidate Biomarkers of Alzheimer's Disease Via Multiplex Cerebrospinal Fluid and Serum Proteomics.

CSF proteomics identifies early changes in autosomal dominant Alzheimer's disease

Detection of biomarkers with a multiplex quantitative proteomic platform in cerebrospinal fluid of patients with neurodegenerative disorders.

Integrative proteomics identifies a conserved Aβ amyloid responsome, novel plaque proteins, and pathology modifiers in Alzheimer's disease

Deep Multilayer Brain Proteomics Identifies Molecular Networks in Alzheimer’s Disease Progression

Alzheimer disease pathology and the cerebrospinal fluid proteome

CSF proteomics in autosomal dominant Alzheimer's disease highlights parallels with sporadic disease

Aβ Amyloid Scaffolds the Accumulation of Matrisome and Additional Proteins in Alzheimer's Disease

Proteomic analysis of Alzheimer's disease cerebrospinal fluid reveals alterations associated with APOE ε4 and atomoxetine treatment

Genetic, Clinical Underpinnings of Brain Change along Two Neuroanatomical Dimensions of Clinically-defined Alzheimer’s Disease

Large-scale proteomic analysis of Alzheimer’s disease brain and cerebrospinal fluid reveals early changes in energy metabolism associated with microglia and astrocyte activation

Alzheimer's disease CSF biomarkers correlate with early pathology and alterations in neuronal and glial gene expression

Proteomic changes in Alzheimer disease associated with progressive Aβ plaque and tau tangle pathologies

Multiplex proteomics identifies novel CSF and plasma biomarkers of early Alzheimer’s disease

Proteomics analysis of prefrontal cortex of Alzheimer's disease patients revealed dysregulated proteins in the disease and novel proteins associated with amyloid-β pathology

Amyloid Accumulation Drives Proteome-wide Alterations in Mouse Models of Alzheimer's Disease-like Pathology

Integrated proteomics and network analysis identifies protein hubs and network alterations in Alzheimer’s disease

Proteogenomic analysis of human cerebrospinal fluid identifies neurologically relevant regulation and implicates causal proteins for Alzheimer's disease

Predictors of Cognitive Decline in Healthy Middle-Aged Individuals with Asymptomatic Alzheimer’s Disease